Approval · Notice of Compliance 1435 · 2000
NAROPIN: Notice of Compliance 1435
Issued November 28, 2000
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 1435
- Date
- November 28, 2000
- Company
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- 1. in thoracic epidural block for acute pain management - 2mg/ml solution continuous infusion for up to 72 hours; 2. in thoracic epidural block for surgical anesthesia - 5 and 7.5 mg/ml solution; 3. in major nerve block for surgical anesthesia - 7.5mg/ml
- Therapeutic class
- Local anesthetic
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NAROPIN | Not yet assigned | — |
Medicinal ingredients
- ROPIVACAINE HYDROCHLORIDE 2 MG per ML
- ROPIVACAINE HYDROCHLORIDE 5 MG per ML
- ROPIVACAINE HYDROCHLORIDE 7.5 MG per ML
- ROPIVACAINE HYDROCHLORIDE 10 MG per ML